Meeting Report

Gastrointestinal Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Nina N. Grenon, DNP, AGCNP-BC, AOCN®

Dana-Farber Cancer Institute


J Adv Pract Oncol 2020;11(6):552-557 | https://doi.org/10.6004/jadpro.2020.11.6.2 | © 2020 Harborside™


  

ABSTRACT

Using coverage from The ASCO Post, Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates findings from two phase III trials, reviews takeaways from the final results of the IDEA study, and discusses what was learned about PARP inhibitor therapy from the TAPUR basket trial.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.